k141_46333_2	SARG|YP_002861121	49.0	51	107	212	2.69e-12	59.3
k141_46333_2	SARG|YP_001779894	47.1	51	107	212	2.72e-11	56.6
k141_46333_2	SARG|YP_001389621	45.1	51	107	212	7.30e-11	55.5
k141_46333_2	SARG|YP_001785579	45.1	51	107	212	1.41e-10	54.7
k141_46333_2	SARG|CAP74085	48.9	47	107	210	7.12e-10	52.8
k141_47629_2	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	32.9	435	419	444	1.63e-63	209
k141_10317_2	SARG|AAD51059	32.2	233	313	323	1.22e-24	100
k141_10317_2	SARG|AAY52004	30.2	281	313	322	1.15e-23	97.8
k141_10317_2	SARG|gi|552942232|ref|WP_023043160.1|	32.3	248	313	323	1.16e-23	97.8
k141_10317_2	SARG|AAD41881	31.6	231	313	323	2.21e-23	97.1
k141_10317_2	SARG|AAD42183	32.2	233	313	322	4.15e-23	96.3
k141_10317_2	SARG|AAR37059	31.2	231	313	323	5.80e-23	95.9
k141_10317_2	SARG|AY082011.1.gene6.p01	31.9	248	313	323	7.99e-23	95.5
k141_10317_2	SARG|NP_878015	29.7	263	313	322	1.92e-21	91.7
k141_10317_2	NCBI|WP_063856710.1|1|1|vanH-Pt2|vanH-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Pt2|AMR|glycopeptide	29.5	264	313	322	1.92e-21	91.7
k141_10317_2	SARG|gi|749574782|ref|WP_040203616.1|	29.3	294	313	323	2.67e-21	91.3
k141_60531_1	SARG|gb|WP_096809342.1|ARO:3007029|salE	46.2	39	99	543	4.46e-06	42.4
k141_60531_2	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	32.9	237	259	343	3.67e-31	117
k141_60531_2	SARG|gb|AAV85982.1|ARO:3000535|macB	35.3	215	259	644	9.29e-30	116
k141_60531_2	SARG|gi|671541568|ref|WP_031525212.1|	34.2	231	259	648	2.39e-27	109
k141_60531_2	SARG|gi|502669352|ref|WP_012905216.1|	36.4	206	259	648	4.35e-25	102
k141_60531_2	SARG|gi|803568669|ref|WP_046077412.1|	38.0	200	259	648	1.09e-24	101
k141_60531_2	SARG|gi|446110352|ref|WP_000188207.1|	38.0	200	259	648	1.09e-24	101
k141_60531_2	SARG|YP_002382193	38.0	200	259	648	1.09e-24	101
k141_60531_2	SARG|gi|803575554|ref|WP_046081557.1|	38.0	200	259	648	1.09e-24	101
k141_60531_2	SARG|gi|446110351|ref|WP_000188206.1|	38.0	200	259	648	1.09e-24	101
k141_60531_2	SARG|gi|1035670474|ref|WP_064517458.1|	36.1	219	259	648	2.71e-24	100
k141_57999_1	ResF|nimE_1_AJ244018_1	47.4	156	156	170	1.22e-41	135
k141_57999_1	megares|MEG_4185|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIME_1	47.4	154	156	152	1.44e-41	135
k141_57999_1	NCBI|WP_005812773.1|1|1|nimE|nimE|nitroimidazole_reductase|2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimE|AMR|nitroimidazole	46.2	156	156	170	1.97e-40	132
k141_57999_1	megares|MEG_4184|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIME_1	46.2	143	156	145	1.01e-37	125
k141_57999_1	ResF|nimH_1_KX576455_1	45.1	153	156	164	4.97e-37	124
k141_57999_1	megares|MEG_4187|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIMH_1	45.0	151	156	152	7.05e-37	123
k141_57999_1	ResF|nimI_1_FJ940883_1	43.9	157	156	165	1.45e-36	122
k141_57999_1	megares|MEG_4192|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIMI_1	43.9	157	156	154	1.50e-36	122
k141_57999_1	megares|MEG_4189|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIMI_1	43.9	155	156	152	2.00e-36	122
k141_57999_1	ResF|nimI_1_FJ940889_1	43.9	157	156	165	2.05e-36	122
k141_57999_3	SARG|AAA22075	45.6	79	116	340	2.43e-13	63.5
k141_57999_3	SARG|1112175A	41.7	84	116	370	6.68e-13	62.4
k141_57999_3	SARG|P07287	41.7	84	116	381	6.79e-13	62.4
k141_57999_3	megares|MEG_2827|Drugs|MLS|23S_rRNA_methyltransferases|ERME_1	41.7	84	116	381	6.79e-13	62.4
k141_57999_3	SARG|AAA26492	40.5	84	116	370	1.11e-11	58.9
k141_57999_3	megares|MEG_2826|Drugs|MLS|23S_rRNA_methyltransferases|ERME_1	40.5	84	116	370	1.11e-11	58.9
k141_57999_3	SARG|P13079	35.0	80	116	299	1.09e-09	53.1
k141_57999_3	SARG|gb|OPG86592.1|ARO:3004626|Erm(49)	35.1	77	116	304	2.81e-09	52.0
k141_57999_3	SARG|gb|CZT31773.1|ARO:3004094|Erm(48)	30.1	83	116	243	5.51e-08	48.1
k141_10407_1	SARG|gi|1004359922|gb|AMP42228.1|	28.6	262	302	639	3.92e-24	101
k141_10407_1	SARG|gb|AMP42147.1|ARO:3004442|tet(W/N/W)	28.4	261	302	639	7.17e-24	100
k141_10407_1	SARG|ABN80187	28.6	262	302	640	7.18e-24	100
k141_10407_1	SARG|ACA23187	28.4	261	302	639	1.31e-23	99.8
k141_10407_1	megares|MEG_7229|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETW_1	28.3	265	302	644	1.32e-23	99.8
k141_10407_1	SARG|gi|254967129|gb|ACT97610.1|	28.4	261	302	639	2.40e-23	99.0
k141_10407_1	SARG|AJ222769.gene.p01	28.4	261	302	639	2.40e-23	99.0
k141_10407_1	SARG|gi|1028100289|ref|WP_063856424.1|	28.4	261	302	639	2.40e-23	99.0
k141_10407_1	SARG|CAX85496	28.4	261	302	639	2.40e-23	99.0
k141_10407_1	SARG|gi|168258996|gb|ACA23181.1|	28.4	261	302	639	2.40e-23	99.0
k141_42561_2	SARG|gi|507050365|ref|WP_016121371.1|	26.3	205	241	309	1.45e-16	76.3
k141_42561_2	SARG|gi|500465078|gb|EOP76697.1|	28.4	204	241	306	2.65e-16	75.5
k141_42561_2	SARG|gi|488067981|ref|WP_002139378.1|	26.8	205	241	309	2.73e-16	75.5
k141_42561_2	SARG|gi|488053456|ref|WP_002124853.1|	26.8	205	241	309	2.73e-16	75.5
k141_42561_2	SARG|gi|487936534|ref|WP_002010000.1|	26.8	205	241	309	2.73e-16	75.5
k141_42561_2	SARG|gi|500448961|gb|EOP61695.1|	26.3	205	241	306	4.99e-16	74.7
k141_42561_2	SARG|gi|488068784|ref|WP_002140181.1|	26.3	205	241	309	7.03e-16	74.3
k141_42561_2	SARG|gi|488120365|ref|WP_002191762.1|	26.8	205	241	309	9.63e-16	73.9
k141_42561_2	SARG|gi|507055561|ref|WP_016126482.1|	26.8	205	241	309	9.63e-16	73.9
k141_42561_2	SARG|gi|447057510|ref|WP_001134766.1|	26.3	205	241	309	9.63e-16	73.9
k141_23247_2	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	28.9	584	552	703	1.49e-65	225
k141_38750_4	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	29.8	171	248	255	9.51e-19	81.6
k141_37433_1	SARG|gb|WP_104671188.1|ARO:3003948|efrA	44.4	302	325	575	6.69e-82	258
k141_37433_1	SARG|gb|AAK76137.1|ARO:3000024|patA	43.0	307	325	564	3.64e-74	237
k141_37433_1	SARG|gi|748767925|ref|WP_040019608.1|	45.6	259	325	623	2.03e-71	231
k141_37433_1	SARG|gi|695842130|ref|WP_032755430.1|	47.0	253	325	603	7.35e-71	229
k141_37433_1	SARG|gi|505420018|ref|WP_015607120.1|	47.0	253	325	603	7.35e-71	229
k141_37433_1	SARG|gi|639148059|ref|WP_024490169.1|	45.6	259	325	602	1.50e-69	226
k141_37433_1	SARG|gi|1045390184|ref|WP_065479071.1|	45.5	253	325	605	1.60e-69	226
k141_37433_1	SARG|gi|817122037|ref|WP_046494699.1|	42.7	274	325	613	1.87e-69	226
k141_37433_1	SARG|gi|516795764|ref|WP_018105258.1|	46.1	254	325	601	2.07e-69	226
k141_37433_1	SARG|gi|517347347|ref|WP_018522839.1|	45.2	259	325	601	5.68e-69	224
k141_34836_1	SARG|gb|AAC74000.1|ARO:3003950|msbA	26.1	261	302	582	3.59e-24	101
k141_34836_1	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	25.1	183	302	574	7.29e-11	61.6
k141_34836_2	SARG|gb|WP_104671188.1|ARO:3003948|efrA	52.3	396	396	575	3.56e-121	362
k141_34836_2	SARG|gb|AAK76137.1|ARO:3000024|patA	36.6	388	396	564	2.33e-74	240
k141_34836_2	SARG|gi|702897513|ref|WP_033300957.1|	44.8	252	396	601	3.04e-65	217
k141_34836_2	SARG|gi|1033217078|gb|OAR27197.1|	42.0	264	396	601	4.24e-65	217
k141_34836_2	SARG|gi|764446018|ref|WP_044369325.1|	43.7	254	396	605	6.39e-65	216
k141_34836_2	SARG|gi|695865802|ref|WP_032778631.1|	42.9	254	396	605	1.74e-64	215
k141_34836_2	SARG|gi|951183771|ref|WP_057661487.1|	43.7	254	396	603	2.34e-64	215
k141_34836_2	SARG|gi|695887424|ref|WP_032788534.1|	42.9	254	396	605	2.43e-64	215
k141_34836_2	SARG|gi|664180077|ref|WP_030714054.1|	42.9	254	396	605	2.43e-64	215
k141_34836_2	SARG|gi|827013130|ref|WP_047175495.1|	43.3	254	396	603	4.57e-64	214
k141_1438_1	SARG|gb|AAD12162.1|ARO:3001299|tlrB	30.2	235	272	280	9.52e-24	96.3
k141_1438_1	SARG|gb|CAB37345.2|ARO:3004592|erm(32)	30.8	237	272	280	9.52e-24	96.3
k141_47797_3	SARG|gi|686132960|ref|WP_031774065.1|	27.4	402	571	668	6.71e-30	123
k141_47797_3	SARG|gi|1028095782|ref|WP_063852670.1|	27.4	402	571	668	8.97e-30	123
k141_47797_3	SARG|gi|1028095795|ref|WP_063852683.1|	27.4	402	571	668	8.97e-30	123
k141_47797_3	SARG|gi|1028095789|ref|WP_063852677.1|	27.1	402	571	668	1.20e-29	122
k141_47797_3	SARG|gi|686196719|ref|WP_031807381.1|	27.1	402	571	668	1.20e-29	122
k141_47797_3	SARG|gi|486697816|ref|WP_001620256.1|	27.1	402	571	668	1.60e-29	122
k141_47797_3	SARG|gi|909708119|ref|WP_049951317.1|	27.1	402	571	649	2.00e-29	122
k141_47797_3	SARG|CAA70425	27.3	462	571	666	2.13e-29	122
k141_47797_3	SARG|gi|487387906|ref|WP_001659608.1|	27.1	402	571	668	2.14e-29	122
k141_47797_3	SARG|gi|916178542|ref|WP_050963202.1|	27.1	402	571	668	2.14e-29	122
k141_2820_2	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.4	521	561	655	5.33e-108	336
k141_2820_2	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.4	521	561	655	7.49e-108	336
k141_2820_2	SARG|gb|AKA86814|ARO:3003746|optrA	37.4	521	561	655	7.49e-108	336
k141_2820_2	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.8	521	561	655	2.09e-107	335
k141_2820_2	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.4	521	561	655	2.93e-107	334
k141_2820_2	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.4	521	561	655	5.80e-107	333
k141_2820_2	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.4	521	561	655	5.80e-107	333
k141_2820_2	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.4	521	561	655	5.80e-107	333
k141_2820_2	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.4	521	561	655	8.16e-107	333
k141_2820_2	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.4	521	561	655	8.16e-107	333
k141_60704_1	SARG|gb|WP_104671188.1|ARO:3003948|efrA	24.0	208	216	575	4.81e-11	60.5
k141_7970_2	SARG|gi|752682279|ref|WP_041330231.1|	41.7	48	107	349	3.08e-09	51.6
k141_7970_2	SARG|gb|MBY8651253.1|ARO:3007189|vanP	59.5	42	107	342	6.91e-08	47.8
k141_7970_2	SARG|CAB61227	50.0	44	107	343	9.44e-08	47.4
k141_7970_2	SARG|gi|765411304|ref|WP_044689514.1|	43.5	46	107	349	1.29e-07	47.0
k141_7970_2	SARG|DQ212986.1.gene8.p01	43.5	46	107	349	1.29e-07	47.0
k141_7970_2	SARG|AAF71281	43.5	46	107	349	1.29e-07	47.0
k141_7970_2	SARG|gi|405945042|pdb|4FU0|A	43.5	46	107	357	1.30e-07	47.0
k141_7970_2	SARG|gi|816206778|gb|AKE81063.1|	47.7	44	107	287	7.98e-07	44.7
k141_7970_2	SARG|gi|447002588|ref|WP_001079844.1|	47.7	44	107	343	8.35e-07	44.7
k141_7970_2	SARG|gi|511041762|ref|WP_016295754.1|	47.7	44	107	343	8.35e-07	44.7
k141_29905_4	SARG|gi|446110305|ref|WP_000188160.1|	50.2	227	231	648	8.81e-73	232
k141_29905_4	SARG|gi|643601187|ref|WP_025237288.1|	50.7	227	231	648	1.23e-72	231
k141_29905_4	SARG|gi|974628291|ref|WP_059215695.1|	50.7	227	231	648	1.23e-72	231
k141_29905_4	SARG|gi|446110298|ref|WP_000188153.1|	50.7	227	231	648	1.23e-72	231
k141_29905_4	SARG|gi|974633183|ref|WP_059219858.1|	50.7	227	231	648	1.23e-72	231
k141_29905_4	SARG|gi|974684692|ref|WP_059267998.1|	50.7	227	231	648	1.23e-72	231
k141_29905_4	SARG|gi|974672242|ref|WP_059256507.1|	50.7	227	231	648	1.73e-72	231
k141_29905_4	SARG|gi|974641719|ref|WP_059227752.1|	50.7	227	231	648	1.73e-72	231
k141_29905_4	SARG|gi|446110299|ref|WP_000188154.1|	50.7	227	231	648	1.73e-72	231
k141_29905_4	SARG|ZP_02903696	50.7	227	231	648	1.73e-72	231
k141_27345_2	SARG|AF155139.2.gene4.p01	36.0	222	256	293	3.61e-31	115
k141_27345_2	NCBI|WP_063856916.1|1|1|vanY-Pt|vanY-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-Pt|AMR|glycopeptide	32.3	235	256	299	2.25e-29	111
k141_27345_2	NCBI|WP_063856920.1|1|1|vanY-Pt|vanY-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-Pt|AMR|glycopeptide	33.1	239	256	296	3.07e-28	108
k141_27345_2	SARG|AAY52007	33.1	239	256	294	4.12e-28	107
k141_27345_2	SARG|gi|503204183|ref|WP_013438844.1|	33.2	211	256	303	4.86e-28	107
k141_27345_2	SARG|gi|1025843957|ref|WP_063576302.1|	39.0	177	256	287	7.03e-28	107
k141_27345_2	SARG|FJ349556.1.gene4.p01	32.1	240	256	233	8.73e-28	105
k141_27345_2	SARG|ACP19238	32.7	211	256	296	1.16e-27	106
k141_27345_2	megares|MEG_7597|Drugs|Glycopeptide|VanA-type_accessory_protein|VANYA_1	32.7	211	256	296	1.16e-27	106
k141_27345_2	SARG|AAA65958	32.7	211	256	303	1.32e-27	106
k141_8045_1	NCBI|XSG12257.1|1|1|drcB|drcB||1|||daptomycin_efflux_ABC_transporter_permease_DrcB|AMR|peptide	38.2	173	180	641	5.46e-25	99.8
k141_8045_2	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	50.4	224	228	255	1.87e-76	230
k141_8045_2	SARG|gi|835330218|ref|WP_047457825.1|	41.3	213	228	648	4.14e-48	166
k141_8045_2	SARG|YP_001453760	41.3	213	228	648	4.14e-48	166
k141_8045_2	SARG|gi|502669352|ref|WP_012905216.1|	41.0	195	228	648	4.14e-48	166
k141_8045_2	SARG|gi|922960663|ref|WP_053388845.1|	41.5	195	228	648	5.74e-48	166
k141_8045_2	SARG|gi|493734654|ref|WP_006683876.1|	38.8	219	228	648	5.74e-48	166
k141_8045_2	SARG|gi|757799695|ref|WP_043016897.1|	41.5	195	228	648	7.95e-48	165
k141_8045_2	SARG|gi|1045891604|ref|WP_065554100.1|	41.5	195	228	648	7.95e-48	165
k141_8045_2	SARG|gi|507082903|ref|WP_016153652.1|	41.5	195	228	648	7.95e-48	165
k141_8045_2	SARG|gi|696368937|ref|WP_032943949.1|	41.5	195	228	648	7.95e-48	165
k141_4166_1	SARG|gb|AAK76136.1|ARO:3000025|patB	42.7	335	393	588	9.94e-79	252
k141_4166_1	SARG|gb|CDO61516.1|ARO:3003949|efrB	39.5	329	393	362	6.95e-75	236
k141_4166_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	36.6	374	393	664	8.37e-75	244
k141_4166_1	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	37.9	351	393	578	6.17e-67	221
k141_4166_1	SARG|gi|748767925|ref|WP_040019608.1|	47.1	238	393	623	2.07e-66	221
k141_4166_1	SARG|gi|943909899|ref|WP_055545300.1|	37.2	341	393	601	7.28e-66	219
k141_4166_1	SARG|gi|497748188|ref|WP_010062372.1|	36.8	334	393	605	7.86e-66	219
k141_4166_1	SARG|gi|948137056|ref|WP_056795395.1|	36.2	334	393	602	3.96e-65	217
k141_4166_1	SARG|gi|1045390184|ref|WP_065479071.1|	36.8	334	393	605	4.19e-65	217
k141_4166_1	SARG|gi|695865802|ref|WP_032778631.1|	36.5	334	393	605	5.85e-65	216
k141_9395_2	megares|MEG_3789|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	32.4	238	383	668	1.54e-20	92.4
k141_9395_2	SARG|gi|686196719|ref|WP_031807381.1|	32.8	238	383	668	1.54e-20	92.4
k141_9395_2	SARG|gi|486697816|ref|WP_001620256.1|	32.4	238	383	668	2.06e-20	92.0
k141_9395_2	SARG|gi|916178542|ref|WP_050963202.1|	32.4	238	383	668	2.06e-20	92.0
k141_9395_2	SARG|gi|282848474|gb|ADB03008.1|	31.9	238	383	668	2.06e-20	92.0
k141_9395_2	SARG|gi|909708119|ref|WP_049951317.1|	32.4	238	383	649	2.70e-20	91.7
k141_9395_2	SARG|CAA73547	32.4	238	383	668	2.76e-20	91.7
k141_9395_2	SARG|gi|727740855|ref|WP_033857946.1|	32.4	238	383	668	2.76e-20	91.7
k141_9395_2	SARG|KC243783.1.gene1.p01	32.4	238	383	668	2.76e-20	91.7
k141_9395_2	SARG|gi|686116460|ref|WP_031766030.1|	32.4	238	383	668	2.76e-20	91.7
k141_48050_2	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	37.3	311	322	712	2.48e-51	179
k141_48050_2	SARG|gb|ABA71733.1|ARO:3002972|vanTG	35.1	308	322	712	9.04e-51	177
k141_48050_2	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	33.9	307	322	711	7.86e-44	158
k141_48050_2	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	34.4	308	322	700	2.17e-41	151
k141_48050_2	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	35.6	298	322	700	2.17e-41	151
k141_48050_2	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	36.0	275	322	700	6.16e-39	144
k141_48050_2	NCBI|WP_063856758.1|1|1|vanTc2|vanTc2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	34.2	298	322	706	1.61e-38	143
k141_11994_3	SARG|gi|555268037|ref|WP_023249477.1|	32.9	213	187	648	1.27e-24	99.0
k141_11994_3	SARG|gi|924626178|ref|WP_053530123.1|	32.9	213	187	648	1.27e-24	99.0
k141_11994_3	SARG|gi|446048013|ref|WP_000125868.1|	33.8	213	187	648	1.72e-24	98.6
k141_11994_3	SARG|gi|924503108|ref|WP_053510027.1|	32.4	213	187	648	5.92e-24	97.1
k141_11994_3	SARG|YP_001571041	32.9	213	187	648	1.10e-23	96.3
k141_11994_3	SARG|gi|960873409|ref|WP_058345546.1|	32.9	213	187	648	1.10e-23	96.3
k141_11994_3	SARG|gi|740610794|ref|WP_038396317.1|	32.4	213	187	648	3.77e-23	94.7
k141_11994_3	SARG|gb|ADZ12699.1|ARO:3005091|RanA	30.8	198	187	258	3.18e-21	86.7
k141_11994_3	SARG|gb|APB03219.1|ARO:3003986|TaeA	30.6	85	187	648	1.05e-06	47.0
k141_12027_3	SARG|gb|WP_011094382.1|ARO:3006903|CAR-1	29.8	114	141	342	3.25e-09	52.8
k141_12027_3	SARG|gb|AJP77059|ARO:3003670|PEDO-1	29.3	99	141	286	4.93e-06	43.5
k141_12027_3	SARG|gb|WP_081853183.1|ARO:3006885|ELM-1	28.6	98	141	313	9.44e-06	42.7
k141_27561_2	SARG|gi|554685678|ref|WP_023185565.1|	23.6	237	257	648	1.20e-18	84.0
k141_27561_2	SARG|gi|923061916|ref|WP_053445667.1|	24.1	237	257	648	1.20e-18	84.0
k141_27561_2	SARG|gi|554689873|ref|WP_023186409.1|	24.1	237	257	648	2.20e-18	83.2
k141_27561_2	SARG|gi|446048047|ref|WP_000125902.1|	24.1	237	257	648	2.20e-18	83.2
k141_27561_2	SARG|gi|1005616587|ref|WP_061695226.1|	24.8	242	257	648	2.98e-18	82.8
k141_27561_2	SARG|gi|919601241|ref|WP_052893936.1|	24.4	242	257	648	2.98e-18	82.8
k141_27561_2	SARG|gi|489039527|ref|WP_002949857.1|	23.6	237	257	648	2.98e-18	82.8
k141_27561_2	SARG|ZP_03074747	24.4	242	257	648	2.98e-18	82.8
k141_27561_2	SARG|gi|910973847|ref|WP_050149048.1|	24.4	242	257	648	4.03e-18	82.4
k141_27561_2	SARG|gi|970558766|ref|WP_058820271.1|	24.4	242	257	648	4.03e-18	82.4
k141_27561_3	SARG|gi|542061059|gb|ERI11611.1|	29.3	222	227	316	4.18e-24	96.7
k141_27561_3	SARG|gb|AAK76137.1|ARO:3000024|patA	27.5	218	227	564	1.37e-16	77.0
k141_27561_3	SARG|gb|CDO61516.1|ARO:3003949|efrB	27.0	152	227	362	3.06e-12	63.9
k141_33890_1	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	29.8	309	350	579	1.70e-33	129
k141_33890_1	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.2	321	350	579	7.18e-32	124
k141_33890_1	SARG|gb|AAC74000.1|ARO:3003950|msbA	25.1	334	350	582	7.56e-30	119
k141_33890_1	SARG|gb|CDO61516.1|ARO:3003949|efrB	39.5	162	350	362	1.10e-29	115
k141_33890_1	SARG|gb|AAK76136.1|ARO:3000025|patB	25.8	360	350	588	3.61e-29	117
k141_33890_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	23.4	329	350	664	6.92e-25	104
k141_33890_1	SARG|gb|WP_104671188.1|ARO:3003948|efrA	28.2	355	350	575	6.52e-24	101
k141_33890_1	SARG|gi|664395661|ref|WP_030922045.1|	24.1	353	350	601	2.28e-23	100
k141_33890_1	SARG|gi|516795764|ref|WP_018105258.1|	23.5	353	350	601	1.02e-22	98.2
k141_33890_1	SARG|gi|639148059|ref|WP_024490169.1|	23.5	353	350	602	1.37e-22	97.8
k141_31507_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	53.1	147	150	664	7.42e-47	159
k141_31507_1	SARG|gi|817122037|ref|WP_046494699.1|	53.5	142	150	613	4.56e-46	157
k141_31507_1	SARG|gb|AAK76136.1|ARO:3000025|patB	51.7	147	150	588	1.30e-45	155
k141_31507_1	SARG|gi|497748188|ref|WP_010062372.1|	52.1	142	150	605	1.56e-45	155
k141_31507_1	SARG|gi|953808775|ref|WP_058042812.1|	50.0	148	150	608	2.23e-45	155
k141_31507_1	SARG|gi|664042835|ref|WP_030582300.1|	52.1	142	150	604	2.97e-45	154
k141_31507_1	SARG|gi|1045390184|ref|WP_065479071.1|	52.1	142	150	605	1.11e-44	153
k141_31507_1	SARG|gi|928900436|ref|WP_053931243.1|	52.1	142	150	600	1.47e-44	152
k141_31507_1	SARG|gi|664579989|ref|WP_031094015.1|	52.1	142	150	601	1.48e-44	152
k141_31507_1	SARG|gi|664170108|ref|WP_030704355.1|	51.4	142	150	603	2.91e-44	152
k141_48201_2	SARG|ZP_04528247	30.8	299	290	279	1.74e-30	114
k141_48201_2	SARG|ZP_03958019	28.8	292	290	317	1.95e-28	110
k141_48201_2	SARG|YP_002929946	28.8	295	290	282	3.80e-28	108
k141_48201_2	SARG|Q7VXA0	29.6	304	290	287	8.22e-27	105
k141_48201_2	SARG|Q7W866	29.6	304	290	287	1.14e-26	104
k141_48201_2	SARG|gi|492817089|ref|WP_005974730.1|	31.4	290	290	272	6.24e-26	102
k141_48201_2	SARG|Q7N0B9	30.5	269	290	272	1.68e-25	101
k141_48201_2	SARG|Q6D159	30.7	290	290	272	3.24e-25	100
k141_48201_2	SARG|YP_002937728	29.9	301	290	289	4.42e-25	100
k141_48201_2	SARG|ZP_04623431	30.5	269	290	272	6.26e-25	99.8
k141_57225_3	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	30.4	289	280	293	2.02e-35	127
k141_57225_3	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	25.9	232	280	568	5.94e-09	55.5
k141_39255_2	NCBI|WP_011860980.1|1|1|blaAHM-1|blaAHM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3-like_metallo-beta-lactamase_AHM-1|AMR|beta-lactam	24.9	245	251	304	1.62e-13	67.8
k141_12200_1	SARG|gi|1035706844|ref|WP_064548272.1|	31.6	79	536	648	2.53e-07	52.4
k141_41833_1	SARG|U82085.gene.p01	23.8	248	220	552	6.16e-09	54.3
k141_41833_1	SARG|GQ205627.2.gene1.p01	22.7	247	220	525	4.87e-08	51.6
k141_41833_2	SARG|GQ205627.2.gene1.p01	47.1	68	91	525	3.40e-14	65.1
k141_41833_2	SARG|FR772051.1.gene9.p01	35.4	82	91	524	1.19e-13	63.5
k141_41833_2	NCBI|AKC61310.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	41.6	77	91	552	7.73e-13	61.2
k141_41833_2	SARG|AAG08983	36.8	87	91	524	1.05e-12	60.8
k141_41833_2	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	30.6	85	91	568	1.45e-12	60.5
k141_41833_2	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	32.9	82	91	524	2.68e-12	59.7
k141_41833_2	NCBI|WP_032492560.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	37.3	75	91	522	1.28e-11	57.8
k141_41833_2	SARG|DQ823382.1.gene1.p01	37.3	75	91	522	1.28e-11	57.8
k141_41833_2	megares|MEG_7687|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	37.3	75	91	522	1.28e-11	57.8
k141_41833_2	megares|MEG_7686|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	37.3	75	91	522	1.28e-11	57.8
k141_45843_1	SARG|gb|AAG04750.1|ARO:3004077|PmpM	22.8	272	277	477	2.24e-17	80.5
k141_27817_2	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	28.6	203	213	359	1.37e-24	98.2
k141_27817_2	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	28.9	211	213	364	9.41e-22	90.5
k141_27817_2	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	28.9	211	213	364	9.41e-22	90.5
k141_27817_2	CARD|gb|AAD51347.1|ARO:3003067|smeS	26.2	210	213	467	6.52e-19	83.2
k141_27817_2	CARD|gb|AEX49906.1|ARO:3003583|basS	27.1	166	213	477	2.27e-16	75.9
k141_3360_1	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	41.6	221	224	228	3.04e-52	167
k141_3360_1	CARD|gb|AAD51348.1|ARO:3003066|smeR	41.6	221	224	229	4.01e-50	162
k141_3360_1	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.4	219	224	220	8.72e-50	160
k141_3360_1	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.4	219	224	219	1.20e-49	160
k141_3360_1	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.4	219	224	220	1.23e-49	160
k141_3360_1	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	37.6	229	224	229	2.27e-49	160
k141_3360_1	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	36.9	233	224	235	7.61e-49	159
k141_3360_1	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.0	219	224	219	9.58e-49	158
k141_3360_1	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	38.2	228	224	232	9.87e-49	158
k141_3360_1	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	38.2	228	224	232	9.87e-49	158
k141_16168_1	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	51.3	450	446	1024	8.92e-161	479
k141_16168_1	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	51.3	450	446	1024	8.92e-161	479
k141_16168_1	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	51.3	450	446	1024	8.92e-161	479
k141_16168_1	SARG|gb|CAA53189|ARO:3000521|mupA	51.3	450	446	1024	8.92e-161	479
k141_16168_1	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	48.6	451	446	1033	2.68e-158	473
k141_16168_1	SARG|gb|AEY83581|ARO:3000510|mupB	48.6	451	446	1033	2.68e-158	473
k141_16168_1	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	37.5	488	446	1107	3.65e-109	346
k141_16168_1	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	37.5	488	446	1107	3.65e-109	346
k141_41959_1	SARG|gb|AAK76137.1|ARO:3000024|patA	27.5	385	413	564	1.53e-27	113
k141_41959_1	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	25.7	350	413	579	7.36e-27	111
k141_41959_1	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	21.8	399	413	579	4.83e-25	106
k141_41959_1	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	25.7	374	413	579	2.41e-22	98.2
k141_41959_1	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	25.4	374	413	579	2.41e-22	98.2
k141_41959_1	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	24.1	377	413	578	8.09e-21	93.6
k141_41959_1	SARG|gb|AYV52072.1|ARO:3002882|lmrD	22.1	349	413	664	1.27e-19	90.1
k141_41959_1	SARG|gb|CDO61516.1|ARO:3003949|efrB	24.2	194	413	362	3.50e-18	84.3
k141_41959_1	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	23.5	353	413	574	1.15e-15	77.8
k141_20127_1	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	49.2	197	198	239	4.52e-63	194
k141_20127_1	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	45.4	196	198	232	2.39e-61	189
k141_20127_1	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	45.4	196	198	232	2.39e-61	189
k141_20127_1	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	48.7	197	198	233	2.46e-61	189
k141_20127_1	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	47.2	199	198	235	4.24e-60	186
k141_20127_1	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	48.5	196	198	231	1.51e-59	185
k141_20127_1	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	48.5	196	198	231	1.51e-59	185
k141_20127_1	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	48.5	196	198	231	4.30e-59	184
k141_20127_1	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	45.4	194	198	231	8.62e-59	183
k141_20127_1	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	45.6	195	198	229	1.63e-58	182
k141_9855_2	SARG|gb|AAC75314.1|ARO:3003578|pmrF	35.0	120	877	322	3.78e-08	55.1
k141_884_2	SARG|ABN79417	39.0	154	237	639	3.28e-23	96.7
k141_884_2	megares|MEG_7177|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	39.0	154	237	639	3.28e-23	96.7
k141_884_2	SARG|NP_348076	34.6	191	237	652	3.31e-23	96.7
k141_884_2	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	39.0	154	237	629	4.41e-23	96.3
k141_884_2	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	39.0	154	237	629	4.41e-23	96.3
k141_884_2	megares|MEG_7173|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	39.0	154	237	629	4.41e-23	96.3
k141_884_2	megares|MEG_7174|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	39.0	154	237	629	4.41e-23	96.3
k141_884_2	NCBI|WP_013646121.1|1|1|tet(O/W/32/O)|tet(O/W/32/O)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_mosaic_protein_Tet(O/W/32/O)|AMR|tetracycline	39.0	154	237	639	4.45e-23	96.3
k141_884_2	SARG|ABF69686	39.0	154	237	639	4.45e-23	96.3
k141_884_2	SARG|ABG81258	39.0	154	237	639	4.45e-23	96.3
k141_59994_2	SARG|gi|985522333|ref|WP_060811962.1|	35.1	319	332	323	3.30e-53	176
k141_59994_2	SARG|gb|AAB05626.1|ARO:3002943|vanHB	35.1	319	332	323	9.19e-53	175
k141_59994_2	SARG|gi|498515089|ref|WP_010815296.1|	34.8	319	332	323	1.82e-52	174
k141_59994_2	SARG|Q47748	35.1	319	332	323	1.82e-52	174
k141_59994_2	SARG|DQ018711.1.gene4.p01	32.4	321	332	322	9.77e-52	172
k141_59994_2	SARG|YP_002333394	34.7	317	332	323	1.00e-51	172
k141_59994_2	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	34.7	317	332	323	1.00e-51	172
k141_59994_2	SARG|AF310956.2.gene5.p01	34.7	317	332	323	1.41e-51	172
k141_59994_2	SARG|gi|740152780|ref|WP_037997109.1|	33.0	321	332	322	7.56e-51	170
k141_59994_2	SARG|gi|737310392|ref|WP_035293250.1|	31.8	321	332	323	3.03e-50	169
k141_33108_2	SARG|gi|823326845|ref|WP_047080664.1|	35.5	231	335	648	6.67e-28	113
k141_33108_2	SARG|Q83LR7	35.8	240	335	648	1.22e-27	112
k141_33108_2	SARG|gi|647325472|ref|WP_025760953.1|	35.8	240	335	648	1.22e-27	112
k141_33108_2	SARG|gi|647323678|ref|WP_025760497.1|	35.8	240	335	648	1.22e-27	112
k141_33108_2	SARG|gi|823302270|ref|WP_047057473.1|	35.5	231	335	648	1.22e-27	112
k141_33108_2	SARG|gi|976146774|ref|WP_059305359.1|	35.5	231	335	648	1.22e-27	112
k141_33108_2	SARG|gi|1022664304|ref|WP_063420886.1|	35.5	231	335	648	1.22e-27	112
k141_33108_2	SARG|gi|823309640|ref|WP_047064288.1|	35.5	231	335	648	1.22e-27	112
k141_33108_2	SARG|gi|505807117|ref|WP_015704872.1|	35.5	231	335	648	1.22e-27	112
k141_33108_2	SARG|gi|518923394|ref|WP_020079269.1|	35.5	231	335	648	1.22e-27	112
k141_33108_3	SARG|gb|AAK76137.1|ARO:3000024|patA	46.8	47	157	564	4.03e-07	47.4
k141_40829_2	SARG|gi|447195835|ref|WP_001273091.1|	27.5	218	454	306	9.27e-17	79.7
k141_40829_2	SARG|ZP_04081918	27.5	218	454	306	9.27e-17	79.7
k141_40829_2	SARG|gi|447195836|ref|WP_001273092.1|	27.5	218	454	306	9.27e-17	79.7
k141_40829_2	SARG|gi|542061059|gb|ERI11611.1|	27.9	215	454	316	1.89e-16	79.0
k141_40829_2	SARG|gi|500448961|gb|EOP61695.1|	27.6	210	454	306	4.13e-16	77.8
k141_40829_2	SARG|P42332	27.1	210	454	306	5.57e-16	77.4
k141_40829_2	SARG|ABB80128	27.1	210	454	306	5.57e-16	77.4
k141_40829_2	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	27.1	210	454	306	5.57e-16	77.4
k141_40829_2	SARG|gi|510143239|gb|AGN36970.1|	27.1	210	454	313	6.02e-16	77.4
k141_40829_2	SARG|YP_001373621	26.7	206	454	318	8.54e-16	77.0
k141_37018_2	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	38.5	221	238	307	1.37e-49	163
k141_37018_2	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	33.2	220	238	293	2.69e-42	144
k141_37018_2	SARG|gi|500194536|ref|WP_011867743.1|	35.8	212	238	306	4.72e-39	136
k141_37018_2	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	36.7	60	238	568	6.85e-07	48.5
k141_42058_1	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	24.3	230	363	341	6.28e-15	73.9
k141_28006_1	SARG|gb|CDO61516.1|ARO:3003949|efrB	30.3	218	439	362	2.98e-13	69.7
k141_13845_3	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	25.2	218	249	494	4.46e-11	61.2
k141_13845_3	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.1	188	249	655	9.00e-11	60.5
k141_13845_3	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.1	188	249	655	9.00e-11	60.5
k141_13845_3	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.5	188	249	655	7.15e-10	57.8
k141_13845_3	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.5	188	249	655	9.60e-10	57.4
k141_13845_3	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.5	188	249	655	9.60e-10	57.4
k141_13845_3	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.5	188	249	655	9.60e-10	57.4
k141_13845_3	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.5	188	249	655	9.60e-10	57.4
k141_13845_3	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.5	188	249	655	9.60e-10	57.4
k141_13845_3	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.5	188	249	655	9.60e-10	57.4
k141_25451_1	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	42.1	561	550	703	5.62e-135	407
k141_58866_2	SARG|gi|445996710|ref|WP_000074565.1|	30.4	224	300	309	1.02e-23	97.4
k141_58866_2	SARG|gi|895808656|emb|COR83787.1|	29.9	224	300	309	1.41e-23	97.1
k141_58866_2	SARG|gi|445996719|ref|WP_000074574.1|	29.9	224	300	309	2.69e-23	96.3
k141_58866_2	SARG|gi|895736250|emb|COF64653.1|	29.9	224	300	309	3.72e-23	95.9
k141_58866_2	SARG|gi|446110087|ref|WP_000187942.1|	29.9	224	300	309	3.72e-23	95.9
k141_58866_2	SARG|gi|445996729|ref|WP_000074584.1|	29.9	224	300	309	5.14e-23	95.5
k141_58866_2	SARG|gi|445996714|ref|WP_000074569.1|	29.9	224	300	309	5.14e-23	95.5
k141_58866_2	SARG|gi|445996722|ref|WP_000074577.1|	30.7	225	300	309	5.14e-23	95.5
k141_58866_2	SARG|gi|445996723|ref|WP_000074578.1|	30.7	225	300	309	7.09e-23	95.1
k141_58866_2	SARG|gi|445996724|ref|WP_000074579.1|	29.5	224	300	309	9.79e-23	94.7
k141_38206_2	SARG|AAB17875	30.0	203	246	274	1.40e-15	73.2
k141_47394_3	SARG|gi|445996719|ref|WP_000074574.1|	43.9	171	184	309	2.67e-38	132
k141_47394_3	SARG|gi|445996710|ref|WP_000074565.1|	43.3	171	184	309	7.42e-38	131
k141_47394_3	SARG|gi|895736250|emb|COF64653.1|	43.3	171	184	309	1.04e-37	130
k141_47394_3	SARG|gi|446110087|ref|WP_000187942.1|	43.3	171	184	309	1.04e-37	130
k141_47394_3	SARG|gi|445996714|ref|WP_000074569.1|	43.3	171	184	309	1.04e-37	130
k141_47394_3	SARG|gi|895808656|emb|COR83787.1|	43.3	171	184	309	1.04e-37	130
k141_47394_3	SARG|gi|507044560|ref|WP_016115614.1|	43.8	169	184	306	1.38e-37	130
k141_47394_3	SARG|gi|445996709|ref|WP_000074564.1|	43.3	171	184	309	1.47e-37	130
k141_47394_3	SARG|gi|445996724|ref|WP_000074579.1|	43.9	171	184	309	1.47e-37	130
k141_47394_3	SARG|gi|814314593|emb|CKF49145.1|	43.3	171	184	309	1.47e-37	130
k141_33264_1	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	32.6	261	261	1024	2.03e-36	135
k141_33264_1	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	32.6	261	261	1024	2.03e-36	135
k141_33264_1	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	33.7	261	261	1033	3.76e-36	135
k141_33264_1	SARG|gb|AEY83581|ARO:3000510|mupB	33.7	261	261	1033	3.76e-36	135
k141_33264_1	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	32.2	261	261	1024	9.41e-36	134
k141_33264_1	SARG|gb|CAA53189|ARO:3000521|mupA	32.2	261	261	1024	9.41e-36	134
k141_33264_1	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	29.7	269	261	1107	3.75e-15	73.9
k141_33264_1	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	29.7	269	261	1107	3.75e-15	73.9
k141_30692_2	SARG|gi|447195835|ref|WP_001273091.1|	38.8	201	283	306	7.97e-35	126
k141_30692_2	SARG|ZP_04081918	38.3	201	283	306	2.18e-34	125
k141_30692_2	SARG|gi|447195836|ref|WP_001273092.1|	38.3	201	283	306	2.18e-34	125
k141_30692_2	SARG|gi|542061059|gb|ERI11611.1|	37.3	212	283	316	3.76e-34	125
k141_30692_2	SARG|gi|507044560|ref|WP_016115614.1|	37.8	201	283	306	4.27e-34	124
k141_30692_2	SARG|gi|500194536|ref|WP_011867743.1|	38.4	203	283	306	5.98e-34	124
k141_30692_2	SARG|gi|445996719|ref|WP_000074574.1|	38.8	201	283	309	6.36e-34	124
k141_30692_2	SARG|gi|500448961|gb|EOP61695.1|	38.8	201	283	306	8.36e-34	124
k141_30692_2	SARG|gi|446026113|ref|WP_000103968.1|	37.3	201	283	306	8.36e-34	124
k141_30692_2	SARG|gi|500465078|gb|EOP76697.1|	38.8	201	283	306	8.36e-34	124
k141_42298_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	44.1	59	63	232	2.47e-13	60.5
k141_42298_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	44.6	56	63	228	3.36e-11	54.7
k141_42298_2	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	42.1	57	63	252	4.31e-07	43.5
k141_2394_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	40.1	222	225	228	5.18e-45	149
k141_2394_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.1	232	225	232	2.31e-44	147
k141_2394_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.1	232	225	232	2.31e-44	147
k141_2394_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.4	228	225	231	2.47e-40	137
k141_2394_2	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.9	229	225	231	3.49e-40	136
k141_2394_2	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	38.6	197	225	231	3.88e-39	134
k141_2394_2	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.6	197	225	231	3.88e-39	134
k141_2394_2	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.3	230	225	231	7.71e-39	133
k141_2394_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	35.7	227	225	232	7.92e-39	133
k141_2394_2	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.2	186	225	231	1.53e-38	132
k141_52508_1	SARG|ZP_04081918	25.8	225	500	306	8.50e-20	89.0
k141_52508_1	SARG|P42332	25.8	225	500	306	1.15e-19	88.6
k141_52508_1	SARG|gi|447195835|ref|WP_001273091.1|	25.8	225	500	306	1.15e-19	88.6
k141_52508_1	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	25.8	225	500	306	1.15e-19	88.6
k141_52508_1	SARG|gi|510143239|gb|AGN36970.1|	25.8	225	500	313	1.27e-19	88.6
k141_52508_1	SARG|ABB80128	25.8	225	500	306	2.10e-19	87.8
k141_52508_1	SARG|gi|447195836|ref|WP_001273092.1|	25.3	225	500	306	2.84e-19	87.4
k141_52508_1	SARG|AAD21213	25.8	225	500	306	3.83e-19	87.0
k141_52508_1	SARG|gi|445996719|ref|WP_000074574.1|	24.9	225	500	309	1.33e-18	85.5
k141_52508_1	SARG|gi|884875933|emb|CKG93789.1|	24.4	225	500	309	3.27e-18	84.3
k141_24397_1	CARD|gb|AAD51347.1|ARO:3003067|smeS	30.1	286	289	467	2.19e-26	106
k141_24397_1	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.4	218	289	381	6.51e-26	104
k141_24397_1	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.4	218	289	381	6.51e-26	104
k141_24397_1	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.7	229	289	381	1.24e-25	103
k141_24397_1	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.7	229	289	381	1.24e-25	103
k141_24397_1	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.3	229	289	381	6.15e-25	101
k141_24397_1	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.3	229	289	381	6.15e-25	101
k141_24397_1	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.8	229	289	381	8.47e-25	101
k141_24397_1	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.8	229	289	381	8.47e-25	101
k141_24397_1	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.5	229	289	381	7.91e-24	98.6
k141_24397_2	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	45.5	231	232	231	3.23e-65	201
k141_24397_2	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	45.0	231	232	231	9.19e-65	199
k141_24397_2	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	44.2	231	232	231	1.49e-63	196
k141_24397_2	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.3	231	232	231	2.11e-63	196
k141_24397_2	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	44.2	231	232	231	2.11e-63	196
k141_24397_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	43.3	231	232	232	3.08e-63	196
k141_24397_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	43.6	227	232	232	8.74e-63	194
k141_24397_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	42.6	230	232	233	2.35e-60	188
k141_24397_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	45.6	226	232	231	4.44e-60	187
k141_24397_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	43.6	225	232	232	1.30e-59	186
k141_43627_1	SARG|gb|CAE00499.1|ARO:3003835|cdeA	27.6	420	454	441	6.43e-41	150
k141_43627_1	SARG|gi|488374619|ref|WP_002444004.1|	25.3	368	454	452	8.29e-36	136
